18 years ago Lorrie was diagnosed with Graves’ disease. Then, in 2017 she received a diagnosis of thyroid cancer. In this episode we hear Lorrie describe the following: * Papillary thyroid cancer * Long delayed pathology results * Graves’ disease * Balancing Graves’ disease and a thyroid cancer diagnosis * Emotional roller coaster of feeling optimistic and other days of sadness. * The feelings and emotions of related to a cancer diagnosis * Being careful about the information shared on the Internet and potential negativity * Support network and family * Nodule size was 1.1 cm, but with history of Graves’ disease, she decided to forego active surveillance
During this episode, the following topics are discussed: 1. Financial burden of surgery versus total cost of active surveillance over ten years. 2. Stretching Exercises for Neck 3. Setting patient expectations prior to FNA to manage anxiety 4. When the laryngeal nerve is severed during thyroid surgery, it can and should be repaired, with proper surgeon skill and training. 5. The most common question asked to Dr. Miyauchi by surgeons from around the world.
In this episode, topics include: * Drug therapy for patients that fail standard therapy; including surgery and RAI * Not all patients have same behavior for their cancer * Some cancers are aggressive * Not many thyroid cancer patients are affected by this; maybe a few thousand in the U.S., but not tens of thousands * What is the treatment protocol for therapy? * Lenvatinib or Sorafenib is the treatment for refectory thyroid cancer * Lenvatinib tends to be more effective * Sorafenib is tolerated by the patient better * Other options to consider include, molecular profiling or some thyroid cancers carry mutation that is targetable, or BRAF * BRAF inhibitors used with thyroid cancer patients * Molecular profiling * DNA sequencing
Kimberly Vanderveen, MD is a Colorado native and graduate of Bear Creek High School in Lakewood, CO. She received her bachelor’s degree with honors from Muhlenberg College in Allentown, PA. She then earned her medical degree from Northwestern University in Chicago, IL in 2001. In this episode, the following topics are discussed: * Two roads of tests: rule out and malignant markers * Rule-out tests picks up innocent behavior pattern. Most common is Afirma * Malignant markers, or rule-in tests, are useful at determining extent of surgery, and help avoid a second or third surgery. ThyroSeq, ThyraMIR, Rosetta * Do patients get both tests? Rule out and behavior? * Approximately 15% of FNA’s come back indeterminate. Some centers as high as 30% * Managing indeterminate nodules when a patient chooses no surgery. * Taking into account emotional, financial, and lifestyle goals of the patient.
Bryan McIver, MD, PhD Dr. McIver contributes to Moffitt Cancer Center almost 20 years of clinical experience in the care of patients with endocrine diseases, specializing in the evaluation of patients with thyroid nodules and thyroid cancer. He has a particular interest in the management of patients with advanced and aggressive forms of cancer and the role of genetic and molecular techniques to improve the accuracy of diagnosis. Most nodules are benign When to do a biopsy How to interpret the results of biopsy Advances in thyroid cancer Ultrasound technology advancements Molecular markers Cytopathology categorizations Molecular marker technologies Gene expression classifier
In this interview, Dr. Kaptein discusses the need to consider each patient before making treatment decisions. In some cases, this may mean foregoing the removal of cancerous lymph nodes.
Carmelo Nucera, M.D., Ph.D., is currently an Assistant Professor at Harvard Medical School, Boston, in the Division of Cancer Biology and Angiogenesis (Department of Pathology), Beth Israel Deaconess Medical Center. Dr. Nucera received his M.D. and Ph.D. in Experimental Endocrinology and Metabolism from Italy. In this episode, Dr. Nucera discusses a combination drug therapy using vemurafenib and palbociclib represents a novel therapeutic strategy to treat papillary thyroid carcinoma (PTC).
In this episode, the following topics are explained: * Optimizing thyroid health prior to conception * Thyroid issues that affect pregnancy * Hypothyroid as result of surgery or Hashimotos * Hyperthyroidism and pregnancy * Adjusting current thyroid treatment, meaning optimizing thyroid levels by adjusting dosage of thyroid medication * TSH levels in light of pregnancy * Planned pregnancy usually means a dose increase
Dr. Paul Y. Casanova-Romero, M.D., M.P.H., F.A.C.P., F.A.C.E, E.C.N.U, que se unió a Palm Beach Diabetes y Endocrine Specialists en 2012, recibió su grado médico con honores (Summa Cum Laude) y Doctor en Ciencias Médicas (DMSc), de la Universidad de Zulia, la Escuela de Medicina en Venezuela. * ¿Cómo se identifican los nódulos y por qué ocurren? autoexamen o en la oficina del médico * La mayoría de los nódulos son benignos pero ocurren porque en mas de 70% de la población * ¿Qué tests puede realizar un médico para evaluar el nódulo? * Ninguna test es 100% * Ultrasonido - qué están buscando en general * Que es ojo fina y el proceso general * Tests moleculares * ¿Qué tipos de resultados se pueden obtener de la citología y qué significan? * La mayoria de ojo finas son benigno
Dr. Bridget Brady is Austin's first fellowship-trained endocrine surgeon. In this episode the following topics are discussed: Austin Thyroid Surgeons sees 30 patients per week with thyroid nodules Up to 80% of US population could have a thyroid nodule(s) less than 5% of Dr Brady's thyroid nodule patients test positive for cancer How relevant is what I don’t know won’t hurt me in thyroid cancer and biopsies of nodules? BETHESDA system or the middle category, also known as indeterminate For thyroid nodules that are indeterminate, historically a surgery would be performed With molecular testing, surgery can be decreased by up to 50% Afirma molecular testing uses messenger RNA If Afirma comes back suspicious it does NOT necessarily mean it is cancer